982 related articles for article (PubMed ID: 26269179)
1. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
2. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
Grant KG; Krisky DM; Ataai MM; Glorioso JC
Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
[TBL] [Abstract][Full Text] [Related]
3. Immunization by Replication-Competent Controlled Herpesvirus Vectors.
Bloom DC; Tran RK; Feller J; Voellmy R
J Virol; 2018 Aug; 92(16):. PubMed ID: 29899091
[TBL] [Abstract][Full Text] [Related]
4. Highly efficient regulation of gene expression by tetracycline in a replication-defective herpes simplex viral vector.
Yao F; Theopold C; Hoeller D; Bleiziffer O; Lu Z
Mol Ther; 2006 Jun; 13(6):1133-41. PubMed ID: 16574491
[TBL] [Abstract][Full Text] [Related]
5. A dominant mutant form of the herpes simplex virus ICP8 protein decreases viral late gene transcription.
Chen YM; Knipe DM
Virology; 1996 Jul; 221(2):281-90. PubMed ID: 8661438
[TBL] [Abstract][Full Text] [Related]
6. The role of ICP4 repressor activity in temporal expression of the IE-3 and latency-associated transcript promoters during HSV-1 infection.
Rivera-Gonzalez R; Imbalzano AN; Gu B; Deluca NA
Virology; 1994 Aug; 202(2):550-64. PubMed ID: 8030221
[TBL] [Abstract][Full Text] [Related]
7. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
Davido DJ; Tu EM; Wang H; Korom M; Gazquez Casals A; Reddy PJ; Mostafa HH; Combs B; Haenchen SD; Morrison LA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950407
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
9. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
Lee LY; Schaffer PA
J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
[TBL] [Abstract][Full Text] [Related]
10. A novel anti-herpes simplex virus type 1-specific herpes simplex virus type 1 recombinant.
Yao F; Eriksson E
Hum Gene Ther; 1999 Jul; 10(11):1811-8. PubMed ID: 10446921
[TBL] [Abstract][Full Text] [Related]
11. ICP0, ICP4, or VP16 expressed from adenovirus vectors induces reactivation of latent herpes simplex virus type 1 in primary cultures of latently infected trigeminal ganglion cells.
Halford WP; Kemp CD; Isler JA; Davido DJ; Schaffer PA
J Virol; 2001 Jul; 75(13):6143-53. PubMed ID: 11390616
[TBL] [Abstract][Full Text] [Related]
12. Herpes simplex virus 1 ICP27 is required for transcription of two viral late (gamma 2) genes in infected cells.
Jean S; LeVan KM; Song B; Levine M; Knipe DM
Virology; 2001 May; 283(2):273-84. PubMed ID: 11336552
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1.
Lowry PW; Koropchak CM; Choi CY; Mocarski ES; Kern ER; Kinchington PR; Arvin AM
Antiviral Res; 1997 Feb; 33(3):187-200. PubMed ID: 9037375
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol suppresses nuclear factor-kappaB in herpes simplex virus infected cells.
Faith SA; Sweet TJ; Bailey E; Booth T; Docherty JJ
Antiviral Res; 2006 Dec; 72(3):242-51. PubMed ID: 16876885
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of herpes simplex virus type 1 early and leaky-late proteins correlates with apoptosis prevention in infected human HEp-2 cells.
Aubert M; Rice SA; Blaho JA
J Virol; 2001 Jan; 75(2):1013-30. PubMed ID: 11134315
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
17. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus-mediated shRNA interference against HSV-1 replication in vitro.
Song B; Liu X; Wang Q; Zhang R; Yang T; Han Z; Xu Y
J Neurovirol; 2016 Dec; 22(6):799-807. PubMed ID: 27566181
[TBL] [Abstract][Full Text] [Related]
19. Construction and characterization of herpes simplex virus type 1 mutants with conditional defects in immediate early gene expression.
Preston CM; Mabbs R; Nicholl MJ
Virology; 1997 Mar; 229(1):228-39. PubMed ID: 9123865
[TBL] [Abstract][Full Text] [Related]
20. The ATM and Rad3-Related (ATR) Protein Kinase Pathway Is Activated by Herpes Simplex Virus 1 and Required for Efficient Viral Replication.
Edwards TG; Bloom DC; Fisher C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
